1
|
Liu S, Ba Y, Li C, Xu G. Inactivation of CACNA1H induces cell apoptosis by initiating endoplasmic reticulum stress in glioma. Transl Neurosci 2023; 14:20220285. [PMID: 37250140 PMCID: PMC10224624 DOI: 10.1515/tnsci-2022-0285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 04/04/2023] [Accepted: 04/16/2023] [Indexed: 05/31/2023] Open
Abstract
Background Ca2+ channels are abnormally expressed in various tumor cells and are involved in the progression of human glioma. Here, we explored the role of a calcium channel, voltage-dependent, T-type, alpha 1H subunit (CACNA1H), which encodes T-type Ca2+ channel Cav3.2 in glioma cells. Methods Cell viability and apoptosis were detected using cell-counting kit-8 and flow cytometry, respectively. The expression of target protein was determined using western blot analysis. Results Cell viability of U251 cells was inhibited significantly after the knockdown of CACNA1H. The apoptosis of U251 cells was enhanced significantly after the knockdown of CACNA1H. Importantly, knockdown of CACNA1H decreased the levels of p-PERK, GRP78, CHOP, and ATF6, indicating that CACNA1H knockdown activated endoplasmic reticulum stress (ERS) in U251 cells. In addition, T-type Ca2+ channel inhibitor NNC55-0396 also induced apoptosis through the activation of ERS in U251 cells. ERS inhibitor UR906 could block CACNA1H inhibitor ABT-639-induced apoptosis. Conclusion Suppression of CACNA1H activated the ERS and thus induced apoptosis in glioma cells. T-type Ca2+ channel inhibitors ABT-639 and NNC55-0396 also induced apoptosis through ERS in glioma cells. Our data highlighted the effect of CACNA1H as an oncogenic gene in human glioma.
Collapse
Affiliation(s)
- Sheng Liu
- Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou, 256603, China
| | - Ying Ba
- Department of Gastroenterology, Binzhou Medical University Hospital, Binzhou, 256603, China
| | - Chenglong Li
- Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou, 256603, China
| | - Guangming Xu
- Department of Neurosurgery, Shandong Provincial Hospital, Shandong University, No. 324, Jingwuweiqi Road, Jinan, 250021, China
| |
Collapse
|
2
|
Raynard C, Ma X, Huna A, Tessier N, Massemin A, Zhu K, Flaman J, Moulin F, Goehrig D, Medard J, Vindrieux D, Treilleux I, Hernandez‐Vargas H, Ducreux S, Martin N, Bernard D. NF-κB-dependent secretome of senescent cells can trigger neuroendocrine transdifferentiation of breast cancer cells. Aging Cell 2022; 21:e13632. [PMID: 35653631 PMCID: PMC9282844 DOI: 10.1111/acel.13632] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 04/22/2022] [Accepted: 05/08/2022] [Indexed: 12/14/2022] Open
Abstract
Cellular senescence is characterized by a stable proliferation arrest in response to stresses and the acquisition of a senescence-associated secretory phenotype, called SASP, composed of numerous factors including pro-inflammatory molecules, proteases, and growth factors. The SASP affects the environment of senescent cells, especially during aging, by inducing and modulating various phenotypes such as paracrine senescence, immune cell activity, and extracellular matrix deposition and organization, which critically impact various pathophysiological situations, including fibrosis and cancer. Here, we uncover a novel paracrine effect of the SASP: the neuroendocrine transdifferentiation (NED) of some epithelial cancer cells, evidenced both in the breast and prostate. Mechanistically, this effect is mediated by NF-κB-dependent SASP factors, and leads to an increase in intracellular Ca2+ levels. Consistently, buffering Ca2+ by overexpressing the CALB1 buffering protein partly reverts SASP-induced NED, suggesting that the SASP promotes NED through a SASP-induced Ca2+ signaling. Human breast cancer dataset analyses support that NED occurs mainly in p53 WT tumors and in older patients, in line with a role of senescent cells and its secretome, as they are increasing during aging. In conclusion, our work, uncovering SASP-induced NED in some cancer cells, paves the way for future studies aiming at better understanding the functional link between senescent cell accumulation during aging, NED and clinical patient outcome.
Collapse
Affiliation(s)
- Clotilde Raynard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Xingjie Ma
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
- Department of Intensive CareThe Affiliated Hospital of Yangzhou University, Yangzhou UniversityYangzhouChina
| | - Anda Huna
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Nolwenn Tessier
- University of Lyon, CarMeN LaboratoryINSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1BronFrance
| | - Amélie Massemin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Kexin Zhu
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Jean‐Michel Flaman
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Florentin Moulin
- University of Lyon, CarMeN LaboratoryINSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1BronFrance
| | - Delphine Goehrig
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Jean‐Jacques Medard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - David Vindrieux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Isabelle Treilleux
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Hector Hernandez‐Vargas
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - Sylvie Ducreux
- University of Lyon, CarMeN LaboratoryINSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1BronFrance
| | - Nadine Martin
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| | - David Bernard
- Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon BérardUniversité de LyonLyonFrance
| |
Collapse
|
3
|
Zhang J, Ding X, Peng K, Jia Z, Yang J. Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression. Aging (Albany NY) 2022; 14:4839-4857. [PMID: 35680563 PMCID: PMC9217695 DOI: 10.18632/aging.204115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 05/19/2022] [Indexed: 11/25/2022]
Abstract
Background: Immunotherapy has a significant effect on the treatment of many tumor types. However, prostate cancers generally fail to show significant responses to immunotherapy owing to their immunosuppressive microenvironments. To sustain progress towards more effective immunotherapy for prostate cancer, comprehensive analyses of the genetic characteristics of the immune microenvironment and novel therapeutic strategies are required. Methods: The transcriptome profiles of patients with prostate cancer were obtained from GEO and processed with the TIDE algorithm to predict their responses to immunotherapy. Next, the significant differentially expressed genes (DEGs) between the responder and non-responder groups were identified and used to compute the co-expression modules by WGCNA. Then, co-expression networks were constructed and survival analysis was applied to hub genes. Finally, drug candidates to alleviate immunosuppression were filtered in prostate cancer using GSEA based on hub genes. Results: In total, we identified 2758 significant DEGs and constructed 16 co-expression modules, seven of which were significantly correlated with the immune response score. In total, 133 hub genes were identified, of which 13 were significantly associated with prostate cancer prognosis. Co-expression networks of hub genes were constructed with KMT2B at the center. Finally, six candidate drugs for prostate cancer immunotherapy were identified in PC3 and LNCaP cell lines. Conclusions: We obtained datasets from multiple platforms, performed integrated bioinformatic analysis to identify 133 hub genes and 13 biomarkers of an immunotherapy response, and six candidate drugs were filtered to inhibit the immunosuppressive tumor microenvironment, to ultimately improve patient responses to immunotherapy in prostate cancer.
Collapse
Affiliation(s)
- Jinpeng Zhang
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China.,Henan Institute of Urology, Tumor Molecular Biology Key Laboratory of Zhengzhou, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China.,Department of Urology, Henan Province People's Hospital, Zhengzhou University People's Hospital, Zheng Zhou University, Zhengzhou, Henan, China
| | - Xiaohui Ding
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China.,Henan Institute of Urology, Tumor Molecular Biology Key Laboratory of Zhengzhou, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China
| | - Kun Peng
- Department of Urology, Henan Province People's Hospital, Zhengzhou University People's Hospital, Zheng Zhou University, Zhengzhou, Henan, China
| | - Zhankui Jia
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China.,Henan Institute of Urology, Tumor Molecular Biology Key Laboratory of Zhengzhou, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China
| | - Jinjian Yang
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China.,Henan Institute of Urology, Tumor Molecular Biology Key Laboratory of Zhengzhou, The First Affiliated Hospital of Zhengzhou University, Zheng Zhou University, Zhengzhou, Henan, China
| |
Collapse
|